OVID · XBRL financial data

Ovid Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (OVID's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	109	142*	148	169	173	76*	130	6,272	132	718*	0	733
Research and development	5,333	10,642*	10,397	12,582	7,855	5,923*	6,659	6,465	5,870	6,589*	11,181	9,957
General and administrative	6,805	7,688*	7,168	8,104	5,544	4,875*	6,021	4,880	6,785	6,422*	6,665	6,474
Total operating expenses	12,138	18,330*	17,565	20,686	13,399	10,798*	12,680	11,345	12,655	13,011*	17,846	16,431
Operating income (loss)	(12,029)	(18,188)*	(17,417)	(20,517)	(13,226)	(10,722)*	(12,550)	(5,073)	(12,523)	(12,293)*	(17,846)	(15,698)
Interest income	—	year only	1,327	991	947	650*	491	384	303	847*	737	1,558
Other income (expense)	776	2,866*	5,723	29,038	(780)	1,469*	2,315	389	365	21,957*	858	689
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(11,252)	(15,322)*	(11,694)	8,521	(14,006)	(9,253)*	(10,235)	(4,684)	(12,158)	9,663*	(16,988)	(15,009)
Earnings per share, basic USD per share	(0.16)	(0.22)*	(0.17)	0.12	(0.20)	—	—	—	—	—	—	—
Earnings per share, diluted USD per share	(0.16)	(0.22)*	(0.17)	0.12	(0.20)	—	—	—	—	—	—	—
Weighted average shares, basic thousands of shares	70,619	70,676*	70,717	70,916	70,976	—	—	—	—	—	—	—
Weighted average shares, diluted thousands of shares	70,619	70,676*	70,717	71,201	70,976	—	—	—	—	—	—	—

Balance sheet

CSV

Fiscal quarters (OVID's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	57,437	27,042	30,772	29,694	15,017	26,301	21,136	28,415	20,611	13,153	94,064	11,327
Marketable securities	29,635	78,792	59,487	47,280	47,695	26,774	21,860	9,932	4,992	56,482	61,458	105,892
Marketable securities, non-current	—	—	—	—	—	0	—	—	—	20,812	10,076	52,550
Prepaid and other current assets	4,642	3,764	2,911	3,915	3,115	2,865	2,925	3,742	3,221	4,733	4,623	6,398
Total current assets	91,713	109,598	93,170	80,889	65,827	55,940	45,921	42,089	28,824	74,368	160,145	123,617
Property and equipment, net	856	769	686	618	509	433	346	285	269	252	217	201
Right-of-use asset	14,155	13,894	13,628	13,357	13,080	12,797	12,509	12,215	11,916	11,610	11,298	10,980
Total assets	125,029	144,027	131,613	118,093	102,654	92,167	81,654	77,428	63,848	150,934	225,628	231,973
Accounts payable	1,217	3,703	3,596	4,720	2,710	3,191	1,950	3,950	1,710	1,956	8,876	4,072
Accrued liabilities	6,222	6,525	4,039	8,108	7,607	5,994	5,997	2,872	2,959	4,899	5,413	4,424
Total current liabilities	8,663	11,474	8,903	14,119	11,630	10,522	9,307	8,924	6,796	8,288	15,748	9,980
Lease liability, non-current	15,073	14,756	14,430	14,099	13,762	13,419	13,070	12,715	12,354	11,986	11,611	11,231
Total liabilities	23,737	56,230	53,333	29,190	26,364	23,941	22,377	21,639	19,150	20,274	27,359	22,083
Accumulated deficit	(262,543)	(277,866)	(289,560)	(281,039)	(295,045)	(304,299)	(314,533)	(319,218)	(331,376)	(321,713)	(338,701)	(353,710)
Total stockholders' equity	101,292	87,797	78,279	88,903	76,290	68,226	59,276	55,789	44,698	130,660	198,269	209,890
Total liabilities and equity	125,029	144,027	131,613	118,093	102,654	92,167	81,654	77,428	63,848	150,934	225,628	231,973
Common shares outstanding (cover page) thousands of shares	70,681	70,710	70,945	70,972	71,010	71,075	71,110	71,110	71,212	131,875	186,640	195,298

Cash flows

CSV

Fiscal quarters (OVID's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(11,252)	(15,322)*	(11,694)	8,521	(14,006)	(9,253)*	(10,235)	(4,684)	(12,158)	9,663*	(16,988)	(15,009)
Stock-based compensation	1,631*	1,789*	1,968	1,740*	1,308*	1,260*	1,284	1,219*	1,109*	1,195*	1,046	1,431*
Depreciation and amortization	146*	141*	136	148*	169*	160*	141	99*	16*	17*	35	16*
Net cash from operating activities	(10,051)*	(11,912)*	(16,686)	(14,255)*	(15,007)*	(10,008)*	(10,280)	(4,774)*	(12,872)*	(10,408)*	(13,899)	(17,594)*
Purchases of property and equipment	5*	14*	19	34*	(4)*	22*	0	0*	0*	0*	—	—
Net cash from investing activities	(4,359)*	(48,516)*	20,188	12,822*	292*	21,292*	5,102	12,053*	5,053*	(72,062)*	5,950	(86,740)*
Proceeds from issuing common stock	—	—	—	—	—	—	0	0*	—	—	2,366	1*
Net cash from financing activities	224*	30,033*	228	356*	38*	0*	13	0*	15*	75,179*	88,982	21,601*
Net change in cash	—	—	—	—	—	year only	(5,165)	7,279*	—	year only	80,911	(82,737)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026
Astria Therapeutics	96,280	706	(32,295)*	57.1M	7.1 quarters	Q3 FY25 10-QSep 30, 2025
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.